BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2023 5:44:49 PM | Browse: 102 | Download: 269
 |
Received |
|
2022-09-06 06:51 |
|
Peer-Review Started |
|
2022-09-06 06:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-11 00:49 |
|
Revised |
|
2022-10-14 11:13 |
|
Second Decision |
|
2022-12-14 03:21 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-12-15 09:36 |
|
Articles in Press |
|
2022-12-15 09:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-12-26 05:52 |
|
Publish the Manuscript Online |
|
2023-01-26 17:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Retrospective Study |
| Article Title |
Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yao-Wei Wang, Xin-Hui Wang, Hong-Xia Wang and Ren-Huan Yu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Research and Development Program of China |
2019YFC1708503 |
|
| Corresponding Author |
Ren-Huan Yu, PhD, Professor, China Department of Nephrology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. tezhongeyu@vip.sina.com |
| Key Words |
Refractory nephrotic syndrome; Idiopathic membranous nephropathy; Low-dose rituximab |
| Core Tip |
According to the Kidney Disease Improving Global Outcomes 2021 guidelines, Rituximab (RTX) is now the first-line therapy for patients with idiopathic membranous nephropathy (IMN). However, the use of RTX for the treatment of patients with refractory IMN remains challenging. We conducted a retrospective study on nine patients with refractory phospholipase A2 receptor (PLA2R)-associated MN to explore the efficacy and safety of a new low-dose RTX regimen (RTX, 200 mg, once a month for five months), and conclude that our low-dose RTX regimen is a promising treatment strategy for refractory PLA2R-associated IMN. |
| Publish Date |
2023-01-26 17:44 |
| Citation |
Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2022; 11(3): 566-575 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i3.566 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
